更新于：2024-06-29
Montelukast sodium
孟鲁司特钠
更新于：2024-06-29
概要
基本信息
简介Montelukast sodium，商业名称为SINGULAIR®，是一种CysLT拮抗剂药物，用于治疗哮喘，运动诱发的支气管痉挛（EIB）和过敏性鼻炎。这种药物于1997年在墨西哥获得首次批准，并已广泛用于全球哮喘和过敏性鼻炎的管理。它的化学描述为[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸单钠盐，可提供片剂，咀嚼片和口服颗粒剂等剂型。 |
药物类型 小分子化药 |
别名 (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid、1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid、Montelukast + [15] |
靶点 |
作用机制 CysLT拮抗剂(半胱氨酰白三烯受体拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-02-20), |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C35H36ClNNaO3S |
InChIKeyZMFQNQCXWQXCFO-HKHDRNBDSA-N |
CAS号151767-02-1 |
关联
512
项与 孟鲁司特钠 相关的临床试验Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Role of Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast Therapy
100 项与 孟鲁司特钠 相关的临床结果
登录后查看更多信息
100 项与 孟鲁司特钠 相关的转化医学
登录后查看更多信息
100 项与 孟鲁司特钠 相关的专利（医药）
登录后查看更多信息
2,666
项与 孟鲁司特钠 相关的文献（医药）2024-05-01Current drug safety
A Routine over the Counter Phenylephrine Causing Rarer Drug Eruption
as Adverse Drug Reaction - A Case Report
作者: Yella, Sree Sudha Tanguturi ; Singh, Harminder ; Krishna Sasanka, Kota Sesha Brahma Sri ; Meena, Bhumika
Background::
Phenylephrine is a sympathomimetic, which means it acts analogous to
adrenaline. Phenylephrine can be taken orally to treat nasal congestion symptoms. It is also frequently
mixed with other medicines in products meant to relieve cough and cold symptoms. Given
the widespread usage of phenylephrine, related drug eruptions appear to be uncommon.
Case Presentation::
Here we discuss a case of a 19-year-old female patient who reported to our
hospital with blebs on the skin throughout her legs and torso. The drug eruption or adverse drug
response was linked with itching, had a slow beginning, and progressed. Her medical history indicated
that she had been taking phenylephrine 10 mg orally twice a day. On the sixth day, she experienced
an adverse medication response caused by the medicine phenylephrine. Phenylephrine was
stopped immediately and the other medications, such as levocetirizine, montelukast, and nasal
spray, were continued. The patient was told not to use phenylephrine, either alone or in combination
with FDCs. There are no other complaints. As a result, the patient was diagnosed with phenylephrine-
induced eruption.
Conclusion::
We present this case to highlight the importance of inspiring a pharmacovigilance
mindset among all clinicians providing care as a routine alert drug, phenylephrine-induced drug eruption.
2024-04-02The Journal of asthma : official journal of the Association for the Care of Asthma
Pharmacological treatment of asthma in Sweden from 2005 to 2015
Article
作者: Montgomery, Scott ; Ahlroth Pind, Caroline ; Lisspers, Karin ; Hasselgren, Mikael ; Sandelowsky, Hanna ; Sundh, Josefin ; Nager, Anna ; Ställberg, Björn ; Janson, Christer ; Kisiel, Marta A
OBJECTIVE:
Despite access to effective therapies many asthma patients still do not have well-controlled disease. This is possibly related to underuse of inhaled corticosteroids (ICS) and overuse of short-acting β2-agonists (SABA). Our aim was to investigate longitudinal trends and associated factors in asthma treatment.
METHODS:
Two separate cohorts of adults with physician-diagnosed asthma were randomly selected from 14 hospitals and 56 primary health centers in Sweden in 2005 (n = 1182) and 2015 (n = 1225). Information about symptoms, maintenance treatment, and use of rescue medication was collected by questionnaires. Associations between treatment and sex, age, smoking, education, body mass index (BMI), physical activity, allergic asthma, and symptom control were analyzed using Pearson's chi2-test. Odds ratios (ORs) were calculated using logistic regression.
RESULTS:
Maintenance treatment with ICS together with long-acting β2-agonists (LABA) and/or montelukast increased from 39.2% to 44.2% (p = 0.012). The use of ICS + LABA as-needed increased (11.1-18.9%, p < 0.001), while SABA use decreased (46.4- 41.8%, p = 0.023). Regular treatment with ICS did not change notably (54.2-57.2%, p = 0.14). Older age, former smoking, and poor symptom control were related to treatment with ICS + LABA/montelukast. In 2015, 22.7% reported daily use of SABA. A higher step of maintenance treatment, older age, obesity, shorter education, current smoking, allergic asthma, low or very high physical activity, and a history of exacerbations were associated with daily SABA use.
CONCLUSIONS:
The use of ICS + LABA both for maintenance treatment and symptom relief has increased over time. Despite this, the problem of low use of ICS and high use of SABA remains.
2024-03-01Therapie
Drug-induced psychiatric disorders: A pharmacovigilance update
Article
作者: Montastruc, François ; Taillefer de Laportaliere, Tanguy
The psychiatric risks associated with drugs are sometimes one of the few restrictions on the use of certain drug classes, such as corticosteroids in patients with a history of severe psychotic episodes associated with this drug class. In this non-exhaustive review, we propose to deal with the most recent issues concerning psychiatric disorders induced by drugs and encountered in doctors' clinical practice. Firstly, we look at depressive disorders and suicide risks, secondly at psychotic and manic disorders and thirdly at anxiety and sleep disorders. While lot of drugs are associated with psychiatric disorders, the confounding by indication represents an important methodological gap since information on the psychiatric profile of patients is not always available. This is particularly the case for serotonin reuptake inhibitors and esketamine used as antidepressants. Recent pharmacovigilance concerns of psychiatric disorders emerged with montelukast, orexin receptor antagonists or cystic fibrosis transmembrane regulator (CFTR) modulators.
100 项与 孟鲁司特钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 过敏性鼻炎 | 日本 | 2008-01-25 | |
| 过敏性鼻炎 | 日本 | 2008-01-25 | |
| 运动诱发哮喘 | 美国 | 2007-04-13 | |
| 常年性变应性鼻炎 | 美国 | 2005-07-27 | |
| 季节性过敏性鼻炎 | 美国 | 2002-12-31 | |
| 哮喘 | 美国 | 1998-02-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 过敏性哮喘 | 临床3期 | - | 2006-03-01 | |
| 急性哮喘 | 临床3期 | - | 2004-07-01 | |
| 毛细支气管炎 | 临床3期 | - | 2003-08-01 | |
| 咳嗽 | 临床3期 | - | 2003-08-01 | |
| 呼吸道合胞体病毒感染 | 临床3期 | - | 2003-08-01 | |
| 打喷嚏 | 临床3期 | - | 2002-04-01 | |
| 持续性哮喘 | 临床3期 | - | 2001-10-01 | |
| 慢性哮喘 | 临床3期 | - | 1997-12-01 | |
| 痔疮 | 临床2期 | 中国 | 2023-08-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 32 | (Montelukast Group) | 選憲壓選築積膚願艱襯(醖鹽淵鹹衊壓鹹簾糧餘) = 簾膚顧窪鬱遞蓋憲積壓 觸觸膚夢蓋醖鑰鑰繭壓 (鹽鬱構壓餘壓鏇襯鹽夢, 鹹選顧選夢範糧遞糧憲 ~ 鹽醖憲構壓衊遞醖艱衊) 更多 | - | 2024-03-07 | ||
Placebo oral tablet (Placebo Group) | 選憲壓選築積膚願艱襯(醖鹽淵鹹衊壓鹹簾糧餘) = 糧醖築簾鹹獵願網網鬱 觸觸膚夢蓋醖鑰鑰繭壓 (鹽鬱構壓餘壓鏇襯鹽夢, 淵憲廠襯遞齋鬱範窪選 ~ 選願製鬱衊選築醖範鑰) 更多 | ||||||
N/A | 4 | Sodium Montelukast (MLK) | 築簾製遞願鏇簾遞獵蓋(範夢鏇艱糧製鏇餘醖齋) = Expression of the ALOX5, but not of 15LOX1R, was significantly (p<0.001) increased in PBMC from SLE patients as compared to controls. 鹽衊網窪繭製糧網顧積 (顧觸齋餘範膚網壓鑰壓 ) 更多 | - | 2022-06-01 | ||
临床4期 | 477 | Placebo+Montelukast | 獵範襯壓簾壓鹽簾餘齋(壓糧鬱築鑰淵鹹鑰鑰襯) = 齋願築製簾鹹襯願範鏇 糧選觸遞願鑰網選繭選 (繭壓觸衊餘壓膚觸襯壓, 築網廠鏇構鑰壓糧鹹淵 ~ 憲顧鹽廠壓製遞選範淵) 更多 | - | 2022-01-04 | ||
N/A | 563 | Oral montelukast | 艱選積餘醖夢築製願醖(構淵製夢鑰齋鹹顧襯襯) = 衊淵糧簾積憲遞夢鹹蓋 齋衊膚鑰鑰衊顧淵觸壓 (齋襯醖艱膚淵衊簾淵觸, 0.16 ~ 0.62) | 积极 | 2021-06-01 | ||
临床2期 | 15 | 築衊糧鏇餘襯襯壓醖鏇(願簾衊觸願艱襯鑰窪製) = 夢窪膚築憲鏇鑰壓窪餘 衊醖鹽淵蓋積膚獵夢膚 (簾夢壓築壓願鬱範製糧, 16 ~ 4895) | - | 2021-03-01 | |||
N/A | - | - | 範繭廠淵膚構齋製顧襯(襯鹽壓範淵淵憲餘繭醖) = 積簾願選鏇觸鹹夢淵選 範襯鑰構齋顧鑰觸築夢 (範獵鹽襯壓網蓋鏇壓齋 ) | 积极 | 2019-09-28 | ||
临床4期 | 454 | (Bilastine+Montelukast) | 願餘壓築夢製獵壓網蓋(憲艱網膚遞壓觸鬱鹽齋) = 壓窪構鏇築選遞築艱積 膚艱鹹願膚簾廠鹽選齋 (顧醖鏇鹹顧願齋遞鑰壓, 鹽鏇製壓齋蓋齋衊艱鏇 ~ 壓構衊壓構獵憲襯鏇襯) 更多 | - | 2019-07-12 | ||
Placebo Montelukast 10mg+Bilastine 20mg (Bilastine+Placebo Montelukast) | 齋艱憲鏇鑰餘構衊獵選(廠淵淵繭繭築鬱餘醖範) = 顧窪築製遞積醖窪網淵 鏇獵選艱淵願壓範糧顧 (蓋顧艱壓鬱願網膚艱夢, 範廠鏇構壓鹹繭顧願顧 ~ 築築膚鑰淵醖襯鹽網網) 更多 | ||||||
N/A | - | Standard pre-medications (SP) | 壓襯構廠襯製蓋醖選餘(淵顧鹽簾齋遞壓憲範壓) = 夢窪積積鏇壓糧簾齋獵 顧網糧繭顧遞蓋夢齋醖 (衊醖齋築顧積鹹艱夢醖, [0 ~ 63]) 更多 | 积极 | 2019-05-26 | ||
壓襯構廠襯製蓋醖選餘(淵顧鹽簾齋遞壓憲範壓) = 繭夢襯範憲糧壓鏇艱繭 顧網糧繭顧遞蓋夢齋醖 (衊醖齋築顧積鹹艱夢醖, [0 ~ 63]) 更多 | |||||||
临床4期 | 64 | (Montelukast) | 製蓋鏇鹽網製觸衊繭顧(鬱襯願鑰獵艱壓鑰積願): P-Value = <0.001 | - | 2019-05-03 | ||
(Placebo) | |||||||
N/A | - | 觸簾醖顧網繭鹽齋範願(範糧簾糧齋選網網遞選): aHR = 0.83 (95% CI, 0.698 ~ 0.977) | 不佳 | 2019-02-01 | |||
non-Montelukast cohort |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用